Skip subpage navigation
In the event the class of drugs specified herein has previously been reviewed, the government solicits quotes for new Blanket Purchase Agreements (BPAs)/Voluntary Agreement for Retail Refunds (VARRs) to replace any existing BPAs/VARRs . The government will not consider existing BPA/VARR prices in the Uniform Formulary (UF) evaluation. Any existing BPA/VARR for this class of drugs will be terminated upon the conclusion of the UF decision.
| Meeting Date |
Review Type |
Drug Classes/New Drugs Under Review/Information for Manufacturers |
Meeting Window for Manufacturers to give Clinical/Cost Presentations |
|
February 2013
|
Class Review |
Topical Pain Agents |
January 2013 |
| Class Review |
Pulmonary-2 Agents: COPD |
| Class Review |
Anticoagulants |
| Designated Newly Approved Drugs |
Intermezzo |
|
May 2013
|
Class Review |
Gout |
March-April 2013 |
| Class Review |
Pulmonary-2 Agent: COPD |
| Class Review |
Tobacco Cessation Agents |
| Class Review |
Pulmonary-2 Agents |
| Clinical Presentations |
Corticosteroids-Immune Modulators |
| Clinical Presentations |
Self-Monitoring Blood Glucose Systems |
| Clinical Presentations |
Lancets |
|
August 2013
|
Class Review |
Corticosteroids-Immune Modulators |
June-July 2013
|
| Class Review |
Self-Monitoring Blood Glucose Systems |
| Class Review |
Rednin-Angiotensin Anithypertensives |
| Clinical Presentations |
Pulmonary-1 Agents |
|
November 2013
|
Class Revew |
Pulmonary-1 Agents |
September-October 2013 |
| Class Review |
Antilipidemics-1 |
| Class Review |
Benign Prostatic Hyperplasia Agents |
| Designated Newly Approved Drugs |
Binosto, Kazano, Nesina, Oseni |
Subject to Change Disclaimer
The Defense Health Agency (DHA) reserves the right to change the classes, sub-classes and/or designated new drugs, and other requirements, of whatever kind, affecting solicitations. The provisions of this table do not constitute a contract, express or implied, between the DHA and manufacturer or eligible bidder.
If the DoD P&T Committee is unable to complete an evaluation of any of the drug classes, the Committee will continue its efforts at the next meeting.
You are leaving Health.mil
The appearance of hyperlinks does not constitute endorsement by the Department of Defense of non-U.S. Government sites or the information, products, or services contained therein. Although the Defense Health Agency may or may not use these sites as additional distribution channels for Department of Defense information, it does not exercise editorial control over all of the information that you may find at these locations. Such links are provided consistent with the stated purpose of this website.
You are leaving Health.mil
View the external links disclaimer.
Last Updated: April 25, 2024